Purpose: The aim of this study was to investigate the short-term retinal sensitivity and metamorphopsia changes after half-fluence photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC). Methods: Patients with acute CSC and evidence of angiographic leakage and subretinal fluid on optical coherence tomography (OCT) were enrolled. Before, and 1 week (W-1) and 2 months (M-2) after PDT, all patients underwent best-corrected visual acuity, enhanced depth imaging OCT, microperimetry (MP) and preferential hyperacuity perimetry (PHP). We considered ‘affected' the Early Treatment of Diabetic Retinopathy Study (ETDRS) sectors showing a mean retinal thickness greater than 350 μm on the baseline OCT thickness map. MP retinal sensitivity, PHP ‘score' and retinal thickness were measured in each ETDRS ‘affected sector'. Functional correlation between MP and PHP was also investigated. Results: Twelve eyes of 12 patients were included. MP and PHP correlated with each other at baseline (p = 0.04) but not at W-1 (p = 0.12) and M-2 (p = 0.05). Mean MP retinal sensitivity slightly improved from 12.9 ± 5.0 dB at baseline to 14.5 ± 4.7 dB at M-2 (p = 0.2). The PHP score changed from 0.33 at baseline to 0.32 at M-2 (p = 0.3). In the ETDRS ‘affected sectors', MP retinal sensitivity improved significantly from 12.9 ± 5.0 dB at baseline to 14.5 ± 4.7 dB at M-2 (p = 0.03), whereas the PHP score did not show significant changes over time. Conclusion: Half-fluence PDT achieved short-term improvement in the sensitivity of the retinal ‘affected sectors' but did not influence metamorphopsia as measured on PHP in patients with acute CSC.

1.
Nicholson B, Noble J, Forooghian F, Meyerle C: Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013;58:103-126.
2.
Yannuzzi LA: Type-A behavior and central serous chorioretinopathy. Retina 1987;7:111-131.
3.
Levine R, Brucker AJ, Robinson F: Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 1989;96:854-859.
4.
Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE: Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19-24.
5.
Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF; Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee: Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2014;121:1073-1078.
6.
Ma J, Meng N, Xu X, Zhou F, Qu Y: System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 2014;92:e594-e601.
7.
Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, Lai TY: Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 2011;7:1378-1386.
8.
Reibaldi M, Boscia F, Avitabile T, Uva MG, Russo A, Zagari M, Occhipinti F, Russo V, Reibaldi A, Longo A: Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2011;151:953-960.
9.
Fujita K, Yuzawa M, Mori R: Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina 2011;31:772-778.
10.
Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O: Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2011;151:303-309.
11.
Ozdemir H, Karacorlu SA, Senturk F, Karacorlu M, Uysal O: Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy. Eye (Lond) 2008;22:204-208.
12.
Amsler M: Earliest symptoms of diseases of the macula. Br J Ophthalmol 1953;37:521-537.
13.
Querques G, Berboucha E, Leveziel N, Pece A, Souied EH: Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. Br J Ophthalmol 2011;95:986-991.
14.
Das R, Shi Y, Silvestri G, Chakravarthy U: Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina 2009;29:1013-1018.
15.
Spaide RF, Koizumi H, Pozzonni MC: Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008;146:496-500.
16.
Querques G, Lattanzio R, Querques L, Triolo G, Cascavilla ML, Cavallero E, Del Turco C, Casalino G, Bandello F: Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function. Retina 2014;34:330-341.
17.
Alster Y, Bressler NM, Bressler SB, Brimacombe JA, Crompton RM, Duh YJ, Gabel VP, Heier JS, Ip MS, Loewenstein A, Packo KH, Stur M, Toaff T; Preferential Hyperacuity Perimetry Research Group: Preferential hyperacuity perimeter (PreView) for detecting choroidal neovascularization study. Ophthalmology 2005;112:1758-1765.
18.
Westheimer G: Visual acuity and hyperacuity. Invest Ophthalmol 1975;14:570-572.
19.
AREDS2-HOME Study Research Group; Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, Heier JS, Kim JE, Garfinkel R: Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 2014;121:535-544.
20.
Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F: Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010;149:307-315.
21.
Richter-Mueksch S, Vécsei-Marlovits PV, Sacu SG, Kiss CG, Weingessel B, Schmidt-Erfurth U: Functional macular mapping in patients with vitreomacular pathologic features before and after surgery. Am J Ophthalmol 2007;144:23-31.
22.
Querques G, Srour M, Massamba N, Georges A, Ben Moussa N, Rafaeli O, Souied EH: Functional characterization and multimodal imaging of treatment-naïve ‘quiescent' choroidal neovascularization. Invest Ophthalmol Vis Sci 2013;54:6886-6892.
23.
Shin JY, Woo SJ, Yu HG, Park KH: Comparison of efficacy and safety between half fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011;31:119-126.
24.
Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F: Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2014;157:1033-1037.
25.
Ojima Y, Tsujikawa A, Hangai M, Nakanishi H, Inoue R, Sakamoto A, Yoshimura N: Retinal sensitivity measured with the micro perimeter 1 after resolution of central serous chorioretinopathy. Am J Ophthalmol 2008;146:77-84.
26.
Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Mizota A, Yuzawa M: Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy. Retina 2014;34:964-970.
27.
Simunovic MP: Metamorphopsia and its quantification. Retina 2015;35:1285-1291.
28.
Baran NV, Gürlü VP, Esgin H: Long-term macular function in eyes with central serous chorioretinopathy. Clin Experiment Ophthalmol 2005;33:369-372.
29.
Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM Jr, Aizman A: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-298.
30.
Ooto S, Hangai M, Sakamoto A, Tsujikawa A, Yamashiro K, Ojima Y, Yamada Y, Mukai H, Oshima S, Inoue T, Yoshimura N: High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology 2010;117:1800-1809.
31.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group: The Neovascular age-related macular degeneration database: multicenter study of 92,976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014;121:1092-1101.
32.
Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T: One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 2011;31:1921-1927.
33.
Oh BL, Yu HG: Choroidal thickness after full-fluence and half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina 2015;35:1555-1560.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.